October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.
News|Articles|September 2, 2026
Eyes on August 2026: MIGS momentum, myopia research, and AI's reality check
Author(s)Martin David Harp
Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.
Advertisement
Advertisement
Retina specialists weighed
Related to this article
Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.
Isa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
Arun C. Gulani, MD, applies his keratoconus classification to cross-linking, rings, transplant, lens surgery, and staged care.
Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.
In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Advertisement
Advertisement